Search - tctmd.com

Displaying 401 - 420 of 595

Sort: Relevancy | Date

Podcast Heart Sounds

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

Caitlin E. Cox

April 25, 2017

News Daily News

Intracoronary Shot of Morphine Fails to Limit Myocardial Infarct Size

Michael O'Riordan

April 07, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds

Todd Neale

December 19, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Daily News

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Shelley Wood

October 07, 2016

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Todd Neale

September 09, 2016

News Daily News

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Caitlin E. Cox

September 08, 2016

Advertisement

Top Stories in Cardiology, April 2017

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

Intracoronary Shot of Morphine Fails to Limit Myocardial Infarct Size

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

FH Screening Started at Time of Childhood Immunization Feasible and Effective

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Trends in Cardiovascular Drug Development Speak to Pipeline Problems and Possibilities

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content